Managers / Q1 2019 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $370M in U.S.-listed holdings across 12 positions for Q1 2019.
Its largest position, UTHR, represents 16.0% of the portfolio.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 99.9% · $370M
- Other · 0.1% · $269,000
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| UTHRUNITED THERAPEUTICS CORP | NEW | +505.3K | 505.3K | +$59M | $59M |
| MCKMCKESSON CORP | NEW | +411.7K | 411.7K | +$48M | $48M |
| ENTAENANTA PHARMACEUTICALS INC | NEW | +476.0K | 476.0K | +$45M | $45M |
| BIIBBIOGEN INC | NEW | +180.0K | 180.0K | +$43M | $43M |
| AMGNAMGEN INC | NEW | +193.7K | 193.7K | +$37M | $37M |
| GILDGILEAD SCIENCES INC | NEW | +558.8K | 558.8K | +$36M | $36M |
| MRKMERCK & CO. INC | NEW | +412.8K | 412.8K | +$34M | $34M |
| ELANELANCO ANIMAL HEALTH INC | NEW | +904.2K | 904.2K | +$29M | $29M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 16.03% | $59M | 505.3K |
| 2 | MCKMCKESSON CORPhistory → | COM | 13.02% | $48M | 411.7K |
| 3 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 12.29% | $45M | 476.0K |
| 4 | BIIBBIOGEN INChistory → | COM | 11.50% | $43M | 180.0K |
| 5 | AMGNAMGEN INChistory → | COM | 9.94% | $37M | 193.7K |
| 6 | GILDGILEAD SCIENCES INChistory → | COM | 9.82% | $36M | 558.8K |
| 7 | MRKMERCK & CO. INChistory → | COM | 9.28% | $34M | 412.8K |
| 8 | ELANELANCO ANIMAL HEALTH INChistory → | COM | 7.84% | $29M | 904.2K |
| 9 | RTI SURGICAL HDS INC | COM | 6.45% | $24M | 3.97M |
| 10 | INVACARE CORP | COM | 3.05% | $11M | 1.35M |
| 11 | AVNSAVANOS MEDICAL INC | COM | 0.72% | $3M | 62.1K |
| 12 | DIGIRAD CORP | COM | 0.07% | $269,000 | 295.2K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.